UroGen Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing novel therapies for urological pathologies. Its lead product candidates, MitoGel and VesiGel are proprietary formulations of the chemotherapy drug Mitomycin C, a generic drug, which is currently used off-label for urothelial cancer treatment in a water-based formulation as an adjuvant or supplemental in post-surgery therapy. The company is developing its product candidates as chemoablation agents, which are designed to remove tumors by non-surgical means, to treat various forms of non-muscle invasive urothelial cancer, including low-grade upper tract urothelial carcinoma, and low-grade bladder cancer. UroGen Pharma Ltd. was incorporated in 2004 and is headquartered in Ra'anana, Israel.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:URGN
CUSIPN/A
Phone972-9770-7601
Debt
Debt-to-Equity RatioN/A
Current Ratio15.18
Quick Ratio15.16
Price-To-Earnings
Trailing P/E Ratio-19.59
Forward P/E Ratio-10.18
P/E GrowthN/A
Sales & Book Value
Annual Sales$8.16 million
Price / Sales70.65
Cash FlowN/A
Price / CashN/A
Book Value$4.98 per share
Price / Book8.42
Profitability
EPS (Most Recent Fiscal Year)($2.14)
Net Income$-20,000,000.00
Net Margins-470.54%
Return on Equity-44.24%
Return on Assets-41.48%
Miscellaneous
Employees42
Outstanding Shares13,750,000
Market Cap$581.13 million
Urogen Pharma (NASDAQ:URGN) Frequently Asked Questions
What is Urogen Pharma's stock symbol?
Urogen Pharma trades on the NASDAQ under the ticker symbol "URGN."
How were Urogen Pharma's earnings last quarter?
Urogen Pharma Ltd (NASDAQ:URGN) released its quarterly earnings results on Tuesday, August, 14th. The company reported ($1.14) EPS for the quarter, missing the Zacks' consensus estimate of ($0.89) by $0.25. The firm earned $0.36 million during the quarter. Urogen Pharma had a negative net margin of 470.54% and a negative return on equity of 44.24%. View Urogen Pharma's Earnings History.
When is Urogen Pharma's next earnings date?
What price target have analysts set for URGN?
8 brokers have issued 1 year price objectives for Urogen Pharma's stock. Their predictions range from $51.00 to $75.00. On average, they anticipate Urogen Pharma's stock price to reach $65.25 in the next year. This suggests a possible upside of 55.6% from the stock's current price. View Analyst Price Targets for Urogen Pharma.
What is the consensus analysts' recommendation for Urogen Pharma?
8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Urogen Pharma in the last year. There are currently 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Urogen Pharma.
What are Wall Street analysts saying about Urogen Pharma stock?
Here are some recent quotes from research analysts about Urogen Pharma stock:
- 1. According to Zacks Investment Research, "UroGen Pharma Ltd. is a clinical stage biopharmaceutical company. It focused on developing urological pathologies with a focus on uro-oncology. The company's product candidates include MitoGel and VesiGel which are in clinical trial stage. Its platform technologies include: RTGel and Immunotherapy. UroGen Pharma Ltd. is based in Ra'anana, Israel. " (10/17/2018)
- 2. Cowen Inc analysts commented, "URGN presented updates for MitoGel’s Phase 3 OLYMPUS trial (topline data in 2Q18)." (11/15/2017)
Who are some of Urogen Pharma's key competitors?
Some companies that are related to Urogen Pharma include Amicus Therapeutics (FOLD), Heron Therapeutics (HRTX), Mallinckrodt (MNK), Myokardia (MYOK), Opko Health (OPK), The Medicines (MDCO), Arena Pharmaceuticals (ARNA), Global Blood Therapeutics (GBT), PTC Therapeutics (PTCT), Pacira Pharmaceuticals (PCRX), Xencor (XNCR), Prestige Consumer Healthcare (PBH), Akcea Therapeutics (AKCA), AnaptysBio (ANAB) and Cambrex (CBM).
Who are Urogen Pharma's key executives?
Urogen Pharma's management team includes the folowing people:
- Mr. Ron Bentsur, CEO & Director (Age 52)
- Mr. Peter P. Pfreundschuh, Chief Financial Officer (Age 49)
- Mr. Stephen Mullennix, Chief Operating Officer
- Ms. Catherine Bechtold, Director of Corp. Communications & Investor Relations
- Dr. Sari Prutchi-Sagiv Ph.D., Marketing Director
When did Urogen Pharma IPO?
(URGN) raised $46 million in an initial public offering on Thursday, May 4th 2017. The company issued 3,500,000 shares at $12.00-$14.00 per share. Jefferies and Cowen and Company acted as the underwriters for the IPO and Raymond James and Oppenheimer were co-managers.
Who are Urogen Pharma's major shareholders?
Which institutional investors are buying Urogen Pharma stock?
How do I buy shares of Urogen Pharma?
Shares of URGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Urogen Pharma's stock price today?
One share of URGN stock can currently be purchased for approximately $41.93.
How big of a company is Urogen Pharma?
Urogen Pharma has a market capitalization of $581.13 million and generates $8.16 million in revenue each year. The company earns $-20,000,000.00 in net income (profit) each year or ($2.14) on an earnings per share basis. Urogen Pharma employs 42 workers across the globe.
What is Urogen Pharma's official website?
How can I contact Urogen Pharma?
Urogen Pharma's mailing address is 9 Ha'Ta'asiya Street, Ra'anana L3, 4365007. The company can be reached via phone at 972-9770-7601 or via email at [email protected]
MarketBeat Community Rating for Urogen Pharma (NASDAQ URGN)
MarketBeat's community ratings are surveys of what our community members think about Urogen Pharma and other stocks. Vote "Outperform" if you believe URGN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe URGN will underperform the S&P 500 over the long term. You may vote once every thirty days.
